Cytochrome P450 polymorphisms with impact in cardiovascular drugs metabolisms in European populations
Autor(a) principal: | |
---|---|
Data de Publicação: | 2022 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10400.22/21938 |
Resumo: | The cytochrome P450 (CYP) enzymes constitute a large polymorphic family that play a huge role in the metabolism of endogenous compounds and in the metabolization of 70–80% of all clinically prescribed medications. Among them, the CYP2C9, CYP2C19, CYP2D6 and CYP4F2 genes are of clinical relevance, as they are highly polymorphic and implicated in the metabolism of several drugs. These genetic polymorphisms which induce variability in CYPs expression present qualitative and quantitative differences between ethnic groups and geographic regions. This review aims to evaluate the allele frequencies, genotypic distribution and predicted CYP2C9, CYP2C19, CYP2D6 and CYP4F2 genetic variants in the European countries. Therefore, a PubMed and a Web of Science search from 1989 to 2021 on the data on the polymorphic prevalence among European countries of the CYP2C9, CYP2C19, CYP2D6 and CYP4F2 genes was performed. After excluding the duplicates, a total of 1179 studies were found. The results were structured and presented in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The present paper is an overview on the frequency CYP genetic variations, facilitating the prediction of a patient's response to medication and, consequently, enabling the selection of personalized medicine |
id |
RCAP_001ee61090e3303764ee78100a507204 |
---|---|
oai_identifier_str |
oai:recipp.ipp.pt:10400.22/21938 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Cytochrome P450 polymorphisms with impact in cardiovascular drugs metabolisms in European populationsCYP2C9CYP2C19CYP2D6CYP4F2European populationsGenetic polymorphismThe cytochrome P450 (CYP) enzymes constitute a large polymorphic family that play a huge role in the metabolism of endogenous compounds and in the metabolization of 70–80% of all clinically prescribed medications. Among them, the CYP2C9, CYP2C19, CYP2D6 and CYP4F2 genes are of clinical relevance, as they are highly polymorphic and implicated in the metabolism of several drugs. These genetic polymorphisms which induce variability in CYPs expression present qualitative and quantitative differences between ethnic groups and geographic regions. This review aims to evaluate the allele frequencies, genotypic distribution and predicted CYP2C9, CYP2C19, CYP2D6 and CYP4F2 genetic variants in the European countries. Therefore, a PubMed and a Web of Science search from 1989 to 2021 on the data on the polymorphic prevalence among European countries of the CYP2C9, CYP2C19, CYP2D6 and CYP4F2 genes was performed. After excluding the duplicates, a total of 1179 studies were found. The results were structured and presented in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The present paper is an overview on the frequency CYP genetic variations, facilitating the prediction of a patient's response to medication and, consequently, enabling the selection of personalized medicineThis work was funded by the Bilateral Cooperation FCT/CAPES 2018/2019 Processo 4.4.1.00 CAPES (CAPES-FCT2017484310P 200.137.174.210). This work was also supported by UIDB/50006/2020 and UIDP/50006/2020 by the Fundação para a Ciência e a Tecnologia (FCT)/Ministério da Ciência, Tecnologia e Ensino Superior (MCTES) through national funds. M. F. Barroso thanks FCT for the FCT Investigator (ref.2020.03107.CEECIND)ElsevierRepositório Científico do Instituto Politécnico do PortoMorais, Stephanie L.Gonçalves, Tiago F.C.Delerue-Matos, CristinaFerrreira-Fernandes, HygorPinto, Giovanny R.Domingues, Valentina F.Barroso, M. Fátima2022-092035-01-01T00:00:00Z2022-09-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.22/21938eng10.1016/j.humgen.2022.201027metadata only accessinfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-03-13T13:18:19Zoai:recipp.ipp.pt:10400.22/21938Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T17:42:02.649202Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Cytochrome P450 polymorphisms with impact in cardiovascular drugs metabolisms in European populations |
title |
Cytochrome P450 polymorphisms with impact in cardiovascular drugs metabolisms in European populations |
spellingShingle |
Cytochrome P450 polymorphisms with impact in cardiovascular drugs metabolisms in European populations Morais, Stephanie L. CYP2C9 CYP2C19 CYP2D6 CYP4F2 European populations Genetic polymorphism |
title_short |
Cytochrome P450 polymorphisms with impact in cardiovascular drugs metabolisms in European populations |
title_full |
Cytochrome P450 polymorphisms with impact in cardiovascular drugs metabolisms in European populations |
title_fullStr |
Cytochrome P450 polymorphisms with impact in cardiovascular drugs metabolisms in European populations |
title_full_unstemmed |
Cytochrome P450 polymorphisms with impact in cardiovascular drugs metabolisms in European populations |
title_sort |
Cytochrome P450 polymorphisms with impact in cardiovascular drugs metabolisms in European populations |
author |
Morais, Stephanie L. |
author_facet |
Morais, Stephanie L. Gonçalves, Tiago F.C. Delerue-Matos, Cristina Ferrreira-Fernandes, Hygor Pinto, Giovanny R. Domingues, Valentina F. Barroso, M. Fátima |
author_role |
author |
author2 |
Gonçalves, Tiago F.C. Delerue-Matos, Cristina Ferrreira-Fernandes, Hygor Pinto, Giovanny R. Domingues, Valentina F. Barroso, M. Fátima |
author2_role |
author author author author author author |
dc.contributor.none.fl_str_mv |
Repositório Científico do Instituto Politécnico do Porto |
dc.contributor.author.fl_str_mv |
Morais, Stephanie L. Gonçalves, Tiago F.C. Delerue-Matos, Cristina Ferrreira-Fernandes, Hygor Pinto, Giovanny R. Domingues, Valentina F. Barroso, M. Fátima |
dc.subject.por.fl_str_mv |
CYP2C9 CYP2C19 CYP2D6 CYP4F2 European populations Genetic polymorphism |
topic |
CYP2C9 CYP2C19 CYP2D6 CYP4F2 European populations Genetic polymorphism |
description |
The cytochrome P450 (CYP) enzymes constitute a large polymorphic family that play a huge role in the metabolism of endogenous compounds and in the metabolization of 70–80% of all clinically prescribed medications. Among them, the CYP2C9, CYP2C19, CYP2D6 and CYP4F2 genes are of clinical relevance, as they are highly polymorphic and implicated in the metabolism of several drugs. These genetic polymorphisms which induce variability in CYPs expression present qualitative and quantitative differences between ethnic groups and geographic regions. This review aims to evaluate the allele frequencies, genotypic distribution and predicted CYP2C9, CYP2C19, CYP2D6 and CYP4F2 genetic variants in the European countries. Therefore, a PubMed and a Web of Science search from 1989 to 2021 on the data on the polymorphic prevalence among European countries of the CYP2C9, CYP2C19, CYP2D6 and CYP4F2 genes was performed. After excluding the duplicates, a total of 1179 studies were found. The results were structured and presented in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The present paper is an overview on the frequency CYP genetic variations, facilitating the prediction of a patient's response to medication and, consequently, enabling the selection of personalized medicine |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022-09 2022-09-01T00:00:00Z 2035-01-01T00:00:00Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10400.22/21938 |
url |
http://hdl.handle.net/10400.22/21938 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1016/j.humgen.2022.201027 |
dc.rights.driver.fl_str_mv |
metadata only access info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
metadata only access |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Elsevier |
publisher.none.fl_str_mv |
Elsevier |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799131507118309376 |